• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
Citation: BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
shu

Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability

More Information
    Graphical Abstract
    • Abstract
  • 〓 Dabigatran etexilate mesylate(DE)and tadalafil(TD)are BCS class II drugs with poor water solubility. 〓 In this study coamorphization technique was used to improve their solubilities/dissolutions and hence to enhance their oral absorptions. The coamorphous DE-TD were prepared by solvent-evaporation method and characterized by PXRD, DSC, FTIR and TGA. In addition, dissolution behavior and physical stability were also investigated. Only halo pattern and a single Tg of 119 °C was observed on the PXRD and DSC of the co-evaporated product, respectively, indicating the formation of coamorphous DE-TD. FTIR result suggested that a hydrogen bond was probably formed between N-H group of DE and C==O group of TD. In comparison to crystalline counterparts, coamorphous DE-TD showed a significantly improved intrinsic dissolution rate and prolonged supersaturation time in intrinsic dissolution and supersaturation dissolution studies, respectively. No crystallization was observed under affecting factors testing(30 days)as well as long-term and accelerated stability testing(90 days)for the prepared coamorphous DE-TD under 25°C/60%RH or 40°C/75%RH, while amorphous DE crystalized at 10 days under 25 ℃/75% RH.
    • FullText(HTML)
    • References (33)
  • [1]
    Guo HH,Miao NN,Li TF,et al.Pharmaceutical coamorphous:a newly defined single-phase amorphous binary system[J].Prog Chem(化学进展),2014,26(2/3):478-486.
    [2]
    Qian S,Heng WL,Wei YF,et al.Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior[J].Cryst Growth Des,2015,15(6):2920-2928.
    [3]
    Gao Y,Liao J,Qi X,et al.Coamorphous repaglinide-saccharin with enhanced dissolution[J].Int J Pharm,2013,450(1/2):290-295.
    [4]
    Loebmann K,Strachan C,Grohganz H,et al.Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions[J].Eur J Pharm Biopharm,2012,81(1):159-169.
    [5]
    Qian S, Li Z, Heng WL, et al. Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride[J].RSC Adv, 2016,6(108):106396-106412.
    [6]
    Chavan RB,Thipparaboina R,Kumar D,et al.Coamorphous systems:a product development perspective[J].Int J Pharm,2016,515(1/2):403-415.
    [7]
    Chen J,Guo HH,Zhang JJ,et al.Physicochemical characteristics of coamorphous simvastatin-gliclazide[J].J China Pharm Univ(中国药科大学学报),2015,46(3):301-308.
    [8]
    Hernandez I,Baik SH,Pinera A,et al.Risk of bleeding with dabigatran in atrial fibrillation[J].JAMA Intern Med,2015,175(1):18-25.
    [9]
    Schulman S,Kearon C,Kakkar AK,et al.Extended use of dabigatran,warfarin,or placebo in venous thromboembolism[J].N Engl J Med,2013,368(8):709-718.
    [10]
    Daugan A,Grondin P,Ruault C,et al.The discovery of tadalafil:a novel and highly selective PDE5 inhibitor.2:2,3,6,7,12,12a-hexahydropyrazino [1′,2′:1,6] pyrido [3,4-b] indole-1,4-dione analogues[J].J Med Chem,2003,46(21):4533-4542.
    [11]
    Humbert M,Lau EM,Montani D,et al.Advances in therapeutic interventions for patients with pulmonary arterial hypertension[J].Circulation,2014,130(24):2189-2208.
    [12]
    Bendayan D,Shitrit D,Kramer MR.Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension:a pilot study[J].Respirology,2008,13(6):916-918.
    [13]
    Kruger S,Haage P,Breuer C,et al.Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography[J].Chest,2001,120(5):1556-1561.
    [14]
    Chai FJ,Sun LL,Ding YF,et al.A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability[J].Nanomedicine,2016,11(14):1801-1816.
    [15]
    U.S.Food and Drug Administration.Center for drug evaluation and research application number 22-5.12[EB].(2010-12-15)[2019-02-10] .http:// www.accessdata.fda.gov/ drugsatfda_ docs/ nda/ 2010/ 022512Orig1s000TOC.cfm.
    [16]
    Wlodarski K,Sawicki W,Haber K,et al.Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Biopharm,2015,94:106-115.
    [17]
    Wei YF,Ling YN,Su ML,et al.Characterization and stability of amorphous tadalafil and four crystalline polymorphs[J].Chem Pharm Bull,2018,66(12):1114-1121.
    [18]
    Hildebrand JH,Scott RL.The solubility of non electrolytes[M].3rd ed.New York:Reinhold Publishing Corporation,1950:153-173.
    [19]
    Greenhalgh DJ,Williams AC,Timmins P,et al.Solubility parameters as predictors of miscibility in solid dispersions[J].J Pharm Sci,1999,88(11):1182-1190.
    [20]
    Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids[J].Polym Eng Sci,1974,14(2):147-154.
    [21]
    Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation[J].Int J Pharm,2011,407(1/2):63-71.
    [22]
    Barton AFM.CRC handbook of solubility parameters and other cohesion parameters [M].2nd ed.Florida:CRC Press,1991:160-185.
    [23]
    Wood J,Syarto J,Letterman H.Improved holder for intrinsic dissolution rate studies[J].J Pharm Sci,1965,54(7):1068.
    [24]
    Wang FY,Zhang Q,Zhang ZY,et al.Solid-state characterization and solubility enhancement of apremilast drug-drug cocrystals[J].CrystEngComm,2018,20(39):5945-5948.
    [25]
    Lobmann K,Grohganz H,Laitinen R,et al.Amino acids as co-amorphous stabilizers for poorly water soluble drugs-part 1:preparation,stability and dissolution enhancement[J].Eur J Pharm Biopharm,2013,85(3):873-881.
    [26]
    Ceric H,Dogan J,Leksic E,et al.Solid state forms of dabigatran etexilate,dabigatran etexilate mysylate and processes for preparation thereof: WO,2012027543A1[P].2012-03-01 [2019-02-16] .
    [27]
    Wizel S,Vant A,Diller D,et al.Tadalafil crystal forms and processes for preparing them:WO,2006050458A2[P].2006-11-11 [2019-02-16] .
    [28]
    Yu L.Amorphous pharmaceutical solids:preparation,characterization and stabilization[J].Adv Drug Deliv Rev,2001,48(1):27-42.
    [29]
    Wlodarski K,Sawicki W,Paluch KJ,et al.The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Sci,2014,62:132-140.
    [30]
    Vyas V,Sancheti P,Karekar P,et al.Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407[J].Acta Pharm,2009,59(4):453-461.
    [31]
    Qian S,Wang SS,Li Z,et al.Charge-assisted bond N+-H mediates the gelation of amorphous lurasidone hydrochloride during dissolution[J].Int J Pharm,2017,518(1/2):335-341.
    [32]
    Guzman HR,Tawa M,Zhang Z,et al.Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations[J].J Pharm Sci,2007,96(10):2686-2702.
    [33]
    Raina SA,Zhang GGZ,Alonzo DE,et al.Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs[J].J Pharm Sci,2014,103(9):2736-2748.
    • Related Articles

  • Related Articles

    [1]LU Yan, CONG Feng, QIAN Shuai, WEI Yuanfeng, ZHANG Jianjun, LIN Yining, GAO Yuan. Enhanced dissolution and eliminated gelation of lenvatinib mesylate by coamorphous system[J]. Journal of China Pharmaceutical University, 2021, 52(1): 44-51. DOI: 10.11665/j.issn.1000-5048.20210106
    [2]ZHAO Yan-rong, DING Li, RAO Ya-kun, TANG Xiao-wen, DING Jun-hong. Stability and degradation products of otilonium bromide in different media[J]. Journal of China Pharmaceutical University, 2010, 41(6): 548-554.
    [3]Stability of influenza vaccine liposome powder[J]. Journal of China Pharmaceutical University, 2010, 41(4): 360-362.
    [4]Content Determination and Stability Research on Diclofenac-Zn[J]. Journal of China Pharmaceutical University, 2002, (3): 92-93.
    [5]Orthogonal Design for Improving the Stability of Compound Vitamin C-Yinqiao Tab Lets[J]. Journal of China Pharmaceutical University, 2000, (6): 17-18.
    [6]Studies on Stability of Lomefloxacin Hydrochloride Injection[J]. Journal of China Pharmaceutical University, 1996, (6): 23-26.
    [7]Studies on Stability during Discoloration of Glucurone Injections and Screening of the Formula[J]. Journal of China Pharmaceutical University, 1995, (2): 75-77.
    [8]Studies on Oxyfedrine Hydrochloride Injection and Its Stability[J]. Journal of China Pharmaceutical University, 1995, (1): 17-19.
    [9]Study on Stability of Dideoxycytidine[J]. Journal of China Pharmaceutical University, 1990, (6): 342-344.
    [10]DISCUSSION OF STABILITY OF THE YIN-YANG EQUATION[J]. Journal of China Pharmaceutical University, 1987, (1): 40-44.

  • Cited by

    Periodical cited type(2)

    1. 周浩，王慧洁，赵媛媛，王欢，张士博. 药品水分测定方法的选择及策略. 中国药科大学学报. 2022(01): 113-119 . 本站查看
    2. 曹麒麟，韩晓璐，高静，郑爱萍，胡春弟. 提高难溶性药物生物利用度的研究进展. 湖北科技学院学报(医学版). 2021(04): 352-356 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (720) PDF downloads (1366) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：415011

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return